Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 22.10.2024 | Passkey Therapeutics Raises $20M in Funding | Passkey Therapeutics, a Cambridge, MA-based developer of synergistic multifunctional therapeutics (SMThs), raised $20M in Seed funding.
The round was led by Breakout Ventures along with Innovation Endeavors and Bison Ventures. Additional pa... |
| - | Passkey | - |
Reviews 0
